The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Consensus recommendations for relapsed/refractory IDH1-mutated AML treatment
Jorge Cortes, MD, The University of Alabama at Birmingham, Birmingham, AL, discusses a recent Delphi consensus paper addressing evidence-based treatment recommendations for patients with relapsed/refractory (R/R) IDH1-mutated acute myeloid leukemia (AML). Dr Cortes reviews the available data supporting the use of ivosidenib and olutasidenib and explains how expert consensus may help guide treatment selection in the absence of direct comparative trials. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
What we wanted to do with this Delphi paper was to get a sort of a consensus among experts in AML, considering that now we have two drugs that are IDH1 inhibitors. Both of them look very good. And what’s the role? Where do we use one? Where there is some evidence to, or is there any evidence to favor one versus the other, et cetera? So we focused on that and try to come up with some, I guess you can call them guidelines to see how you can use it...
What we wanted to do with this Delphi paper was to get a sort of a consensus among experts in AML, considering that now we have two drugs that are IDH1 inhibitors. Both of them look very good. And what’s the role? Where do we use one? Where there is some evidence to, or is there any evidence to favor one versus the other, et cetera? So we focused on that and try to come up with some, I guess you can call them guidelines to see how you can use it. Of course, part of that is that based on the data, both seem to be very good drugs. There’s some advantages of each one of them. With olutasidenib, the remission duration looks very good. There’s a little bit of data, post-venetoclax data, that looks positive. With ivosidenib, we have a long history of use safety and frontline therapy good results so you know it was just trying to guide our colleagues on where you can use them as much as possible based on the available data considering that very likely we’re never going to see a randomized trial, so it’s mostly based on available evidence, experience, etc.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
